Skye Bioscience (SKYE) Non-Current Assets (2012 - 2026)
Skye Bioscience (SKYE) posted quarterly Non-Current Assets of $849767.0 for Q1 2026, down 51.87% year-over-year from $1.8 million in Q1 2025, and down 30.32% quarter-over-quarter from $1.2 million in Q4 2025.
Skye Bioscience (SKYE) Non-Current Assets (2012 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Non-Current Assets for 15 consecutive years, with $849767.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 51.87% year-over-year to $849767.0; the TTM figure through Mar 2026 stood at $5.0 million (down 11.24% YoY), while the FY2025 annual figure was $1.2 million, down 37.03% from the prior year.
- Non-Current Assets eased to $849767.0 in Q1 2026 per SKYE's latest filing, from $1.2 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $1.9 million in Q4 2024 and bottomed at $136040.0 in Q1 2023.
- Historically, Non-Current Assets has averaged $755897.9 across 5 years, with a median of $318141.0 in 2023.
- Annual changes were most pronounced in 2022 — Non-Current Assets jumped 1175.0% — and 2026, when it sank 51.87%.
- Skye Bioscience's Non-Current Assets stood at $167354.0 in 2022, then jumped by 73.03% to $289568.0 in 2023, then soared by 568.76% to $1.9 million in 2024, then tumbled by 37.03% to $1.2 million in 2025, then plunged by 30.32% to $849767.0 in 2026.
- Business Quant data shows SKYE's Non-Current Assets at $849767.0 in Q1 2026, $1.2 million in Q4 2025, and $1.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.70 Bn | 131.85 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.36 Bn | 60.18 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 59.15 Bn | 54.01 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.88 Bn | 28.57 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 18.06 Bn |
| 10 | Skye Bioscience | 10.56 Mn | 10.56 Mn | - | 74,908.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 849,767.00 |
| Dec 31, 2025 | 1.22 Mn |
| Sep 30, 2025 | 1.40 Mn |
| Jun 30, 2025 | 1.58 Mn |
| Mar 31, 2025 | 1.77 Mn |
| Dec 31, 2024 | 1.94 Mn |
| Sep 30, 2024 | 1.73 Mn |
| Jun 30, 2024 | 257,068.00 |
| Mar 31, 2024 | 265,189.00 |
| Dec 31, 2023 | 289,568.00 |
| Sep 30, 2023 | 318,141.00 |
| Jun 30, 2023 | 343,257.00 |
| Mar 31, 2023 | 136,040.00 |
| Dec 31, 2022 | 167,354.00 |
| Sep 30, 2022 | 185,536.00 |
| Jun 30, 2022 | 193,542.00 |
| Mar 31, 2022 | 218,012.00 |
| Dec 31, 2021 | 242,991.00 |
| Sep 30, 2021 | 253,279.00 |
| Jun 30, 2021 | 19,563.00 |